View in EDS PDF Full Text

Comprehensive approaches in Alzheimer’s disease: from general aspects to stem cell therapy and antidiabetic use.

Saved in:
Bibliographic Details
Title: Comprehensive approaches in Alzheimer’s disease: from general aspects to stem cell therapy and antidiabetic use.
Alternate Title: Enfoques integrales en la enfermedad de Alzheimer: desde aspectos generales hasta la terapia con células madre y el uso de antidiabéticos.
Authors: Murguiondo-Pérez, Renata1, Bautista-Gonzalez, Maria F.1, Cano-Herrera, Gabriela2, Méndez-Vionet, Amairani3, Vargas-Sánchez, Montserrat1, Vélez-Rodríguez, Ignacio4, Torres-Jiménez, María J.1, Garibaldi-Bernot, Franco1, Esparza Salazar, Felipe1,5 felipe.esparzas69@anahuac.mx
Source: Revista Mexicana de Neurociencia. May/Jun2025, Vol. 26 Issue 3, p95-102. 8p.
Subjects: NEURAL stem cells, STEM cell treatment, INSULIN resistance, TAU proteins, HYPOGLYCEMIC agents
Abstract (English): Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-ß and Tau protein in brain tissue. AD represents 80% of the cases of dementia worldwide, affecting more than 7.29 million people with an increase in incidence of 147.95% in the past 30 years. At present, conventional treatments for this condition remain limited, which has led to a significant increase in its incidence and prevalence. In this paper, we address general aspects regarding AD, from its pathophysiology, diagnostic methods, and its association with insulin resistance; as well as present treatments and new alternatives, specifically hypoglycemic agents, such as metformin, liraglutide and insulin; and neural stem cells. It is concluded that stem cell and antidiabetic treatments had positive results in preclinical studies, so more future studies are required to consider them safe in humans. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): La AD es una enfermedad neurodegenerativa progresiva caracterizada por la acumulación de placas de Aß y de proteína Tau en el tejido cerebral. La AD representa el 80% de las etiologías de demencia afectando a más de 7.29 millones de personas con un incremento del 147.95% en su incidencia. Actualmente los tratamientos convencionales para esta condición siguen siendo limitados, lo que ha conllevado al aumento en su incidencia y prevalencia. En este texto abordamos generalidades de AD, desde su fisiopatología, métodos diagnósticos y su relación con la resistencia a la insulina; así como tratamientos actuales y nuevas alternativas, específicamente hipoglucemiantes como la metformina, liraglutida y la insulina, y células madre neurales. Se concluye que los tratamientos con células madre y antidiabéticos tuvieron resultados positivos en estudios preclínicos, por lo que se requieren más estudios futuros para poder considerarlos seguros en humanos. [ABSTRACT FROM AUTHOR]
Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 186002027
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Comprehensive approaches in Alzheimer’s disease: from general aspects to stem cell therapy and antidiabetic use.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Enfoques integrales en la enfermedad de Alzheimer: desde aspectos generales hasta la terapia con células madre y el uso de antidiabéticos.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Murguiondo-Pérez%2C+Renata%22">Murguiondo-Pérez, Renata</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Bautista-Gonzalez%2C+Maria+F%2E%22">Bautista-Gonzalez, Maria F.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Cano-Herrera%2C+Gabriela%22">Cano-Herrera, Gabriela</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Méndez-Vionet%2C+Amairani%22">Méndez-Vionet, Amairani</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Vargas-Sánchez%2C+Montserrat%22">Vargas-Sánchez, Montserrat</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Vélez-Rodríguez%2C+Ignacio%22">Vélez-Rodríguez, Ignacio</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Torres-Jiménez%2C+María+J%2E%22">Torres-Jiménez, María J.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Garibaldi-Bernot%2C+Franco%22">Garibaldi-Bernot, Franco</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Esparza+Salazar%2C+Felipe%22">Esparza Salazar, Felipe</searchLink><relatesTo>1,5</relatesTo><i> felipe.esparzas69@anahuac.mx</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Revista+Mexicana+de+Neurociencia%22">Revista Mexicana de Neurociencia</searchLink>. May/Jun2025, Vol. 26 Issue 3, p95-102. 8p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22NEURAL+stem+cells%22">NEURAL stem cells</searchLink><br /><searchLink fieldCode="DE" term="%22STEM+cell+treatment%22">STEM cell treatment</searchLink><br /><searchLink fieldCode="DE" term="%22INSULIN+resistance%22">INSULIN resistance</searchLink><br /><searchLink fieldCode="DE" term="%22TAU+proteins%22">TAU proteins</searchLink><br /><searchLink fieldCode="DE" term="%22HYPOGLYCEMIC+agents%22">HYPOGLYCEMIC agents</searchLink>
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-ß and Tau protein in brain tissue. AD represents 80% of the cases of dementia worldwide, affecting more than 7.29 million people with an increase in incidence of 147.95% in the past 30 years. At present, conventional treatments for this condition remain limited, which has led to a significant increase in its incidence and prevalence. In this paper, we address general aspects regarding AD, from its pathophysiology, diagnostic methods, and its association with insulin resistance; as well as present treatments and new alternatives, specifically hypoglycemic agents, such as metformin, liraglutide and insulin; and neural stem cells. It is concluded that stem cell and antidiabetic treatments had positive results in preclinical studies, so more future studies are required to consider them safe in humans. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: La AD es una enfermedad neurodegenerativa progresiva caracterizada por la acumulación de placas de Aß y de proteína Tau en el tejido cerebral. La AD representa el 80% de las etiologías de demencia afectando a más de 7.29 millones de personas con un incremento del 147.95% en su incidencia. Actualmente los tratamientos convencionales para esta condición siguen siendo limitados, lo que ha conllevado al aumento en su incidencia y prevalencia. En este texto abordamos generalidades de AD, desde su fisiopatología, métodos diagnósticos y su relación con la resistencia a la insulina; así como tratamientos actuales y nuevas alternativas, específicamente hipoglucemiantes como la metformina, liraglutida y la insulina, y células madre neurales. Se concluye que los tratamientos con células madre y antidiabéticos tuvieron resultados positivos en estudios preclínicos, por lo que se requieren más estudios futuros para poder considerarlos seguros en humanos. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=186002027
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.24875/RMN.24000049
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 95
    Subjects:
      – SubjectFull: NEURAL stem cells
        Type: general
      – SubjectFull: STEM cell treatment
        Type: general
      – SubjectFull: INSULIN resistance
        Type: general
      – SubjectFull: TAU proteins
        Type: general
      – SubjectFull: HYPOGLYCEMIC agents
        Type: general
    Titles:
      – TitleFull: Comprehensive approaches in Alzheimer’s disease: from general aspects to stem cell therapy and antidiabetic use.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Murguiondo-Pérez, Renata
      – PersonEntity:
          Name:
            NameFull: Bautista-Gonzalez, Maria F.
      – PersonEntity:
          Name:
            NameFull: Cano-Herrera, Gabriela
      – PersonEntity:
          Name:
            NameFull: Méndez-Vionet, Amairani
      – PersonEntity:
          Name:
            NameFull: Vargas-Sánchez, Montserrat
      – PersonEntity:
          Name:
            NameFull: Vélez-Rodríguez, Ignacio
      – PersonEntity:
          Name:
            NameFull: Torres-Jiménez, María J.
      – PersonEntity:
          Name:
            NameFull: Garibaldi-Bernot, Franco
      – PersonEntity:
          Name:
            NameFull: Esparza Salazar, Felipe
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May/Jun2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 16655044
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Revista Mexicana de Neurociencia
              Type: main
ResultId 1